Introduction
Since chorionic villus sampling (CVS) was established as a first-trimester alternative to amniocentesis for the prenatal detection of genetic disorders four years ago [3, 15, 16] , three major reports from different centers with about 1000 cases each have recently provided valuable informations on the safety of sampling and the reliability of diagnosis [4, 13, 17 ]. An editorial in the "Lancet" at the beginning of 1986 concluded from the discussion at the 2nd International Conference on CVS in Birmingham that "the best technique of CVS is not yet agreed" [1] . Most samples are at present obtained transcervically by a specific type of plastic catheter with a bendable aluminum obturator which was originally developed by H. WARD [15] . A disadvantage of this particular instrument can be an occasionally significant reduction in visibility on the ultrasound screen after removal of the metal obturator with resulting loss of control over the catheter tip during sampling. We therefore started in 1984 to develop a CVS catheter with improved echogenicity [5] and ultimately have used in our diagnostic series a transparent polyethylene catheter (figure 1 a) with a highly echogenic stripe in its wall (figure 1 b). Here our experience with more than 500 diagnostic cases using this technique and their complete follow-up according to an investigative protocol is reported.
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Methodology
The diagnostic CVS program at the University of Münster, F. R. G., started after approval of our protocol by the Institutional Ethics Comittee on Human Research at the beginning of 1985. All patients received detailed genetic counseling before the procedure and the statistical uncertainties of the risk evaluation due to the yet limited experience with CVS were specifically stressed [6] . Samplings were performed between 8 and 13 weeks from the last menstrual period with the use of our echogenic catheter (Angiomed, Karlsruhe, F. R. G.) which has a length from 20 to 26 cm and a diameter of 1.1 mm so that the dilatation of the cervix before the procedure is not required. After removal of the oburator there is no impairment in the visibility of the catheter due to its echogenic stripe ( figure 2 ). In all cases we determined maternal serum alpha-fetoprotein values before and after sampling. Maternal serum samples were drawn immediately before and shortly after CVS for AFP determinations by radioimmunoassay with commercially available kits with proper quality control (Professor FUHRMANN, Giessen).
In the last 403 cases we took swabs from the cervical os for bacteriological studies before the cervical desinfection with polyvinylpyrrolidoneiodine-complex and cultured the tip of the catheter after the procedure. In 124 consecutive cases estradiol, progesterone and ß-HCG were measured with commercially available kits before the procedure, especially in those cases where ultrasound evaluation revealed, despite fetal heart action, findings suspicious of threatening abortion prompting us to wait with the sampling.
All patients were requested to fill out a questionnaire before the procedure with inquiries about their medical history and some socioeconomic factors. The procedures were done under continuous ultrasound visualization with a 3.5 MHz sector transducer (Sono-line SL, Siemens, Erlangen, F. R. G.).
Immediately after sampling the tissue was placed in Petri dishes with RPMI medium and evaluated under a dissecting microscope ( 60 -100). Chorionic villi were separated and transferred by forceps into clean medium, washed and evaluated again microscopically in order to separate any decidual contamination. In cases with blood admixture heparin was added to the sample. The amount of tissue was evaluated by comparison with photographically documented reference standards [16] . In all cases long term cultures were established in Chang's medium (Hana Biologicals, Berkeley, California) and direct preparations were also performed routinely for the last 270 cases. In cases of female fetal karyotypes maternal cell contamination was excluded by comparison of fluorescence polymorphisms [14] , when no metaphases from direct preparations were available.
The samplings took place as an outpatient procedure. All patients with ongoing pregnancies were seen again at 16 weeks after the last menstrual period for a detailed ultrasound follow-up and maternal serum AFP screening. All the relevant birth informations were mailed to us by a standardized questionnaire, and if necessary, follow-up was completed by telephone. All cases were documented on the data sheets of the International CVS Registry kindly provided by L. JACKSON, Philadelphia, USA, and all data were recorded on computer.
Results
The indications for CVS are in accordance with those for amniocentesis with the exception of neural tube defects (table I).
The one case for paternity testing using HLA antigen determination was investigated prior to a scheduled termination of pregnancy in the course of a legal investigation following rape (HLA-testing by Professor H. GROSSE-WILDE, Essen). The 7 cases at risk for sickle cell anemia or thalassemias were examined by DNA-studies [9] following an active screening program in Germany by our group. Of 8 patients at risk for Duchenne muscular dystrophy 3 had female fetuses and DNA-analysis was performed in the remaining 5 pregnancies at risk for hemophilia A. A female karyotype was found in two cases and a Turner syndrome in one. By DNA analy- The bacteriologic studies on the cervical swabs revealed aerobic and/or anaerobic bacterial contamination in almost all cases, but a positive culture of the catheter tip was only encountered in 46 out of 403 cases (12%) including 23 cases with discordant bacteriologic findings in the cervix and catheter possibly suggesting secondary contamination [8] . Table II outlines the abnormal results. Terminations of pregnancy due to pathologic results were only performed in 13 cases (2.6%). In one case each of true trisomy 18 and 9 mosaicism and two cases with true marker chromosome mosaicism amniocentesis was performed which could not confirm the CVS findings, and the pregnancies are continuing uneventfully in two patients and resulted in a normal child in the other case with mosaic marker chromosomes.
Until December 1986 a total of 223 deliveries were documented.
So far we have complete records of pregnancy outcome from 259 cases; only two patients with intact pregnancy at 17 weeks were lost to follow-up due to move to the USA. There was a more than 20% increase in maternal serum AFP levels in about 53% of the patients after CVS in our series [2] . The rises in maternal AFP levels showed a statistically significant positive correlation to the sample weights, but we did not observe a statistically significant correlation with the number of insertions so far.
At least 7% spontanous abortions in the group of patients counseled before the sampling by sonography at the time of our first examination and about 3% of the intact pregnancies ended in spontaneous miscarriage between our first scan which had shown fetal heart action and the scheduled CVS date. In this latter group low levels of maternal estradiol, ß-HCG and especially progesterone were indicative of threatened abortion in 82% of the cases. Of interest is the observation of a fetal trisomy 18 with a significant drop of all three hormone levels prior to sampling and an ultrasonically still viable pregnancy 9 days after sampling immediately before spontanous abortion occured.
Of the 501 samplings 21 failed, but the rate of unsuccessful sampling decreased significantly with increasing experience and is now about 1%. The break-down of gestational ages is given in table III, sample weights and number of insertions in table IV and V, respectively. In the 486 pregnancies which were intended to continue 21 fetal losses occured prior to 28 weeks, of pregnancy. This abortion rate of 4.3% is not higher than the background rate seen in pregnancies without intervention matched for maternal age [20] . In WILSON'S series [20] of follow-up investigations of women with normal ultrasound scans at 7 to 12 weeks 6 out of 133 pregnancies ended in spontaneous abortions already at 20 weeks gestation or less. The newborn parameters of the 223 babies delivered so far were within the expectation for our population and there was no indication for an increase in the rate of placental abnormalities or growth retardation. There were 2 still-births and 4 neonatal deaths, one in a prematurely delivered twin pregnancy. There is no indication for an increased rate of birth defects in our series.
Our questionnaire study [7] indicated that patients with higher socio-economic backgrounds were clearly overrepresented. The patients had received the primary information about CVS from their obstetrician in 74%, from other doctors in 6%, media in 7% and family members or other sources in 13%. The fetal loss rate (4.3%) in our series is in accordance with the reports from other centers [12] and does not differ significantly from the reported rates of spontaneous abortions in the first trimester [4] . The abortion rate may be a reflection of our practice of relatively low "aggressiveness in seeking in analyzable sample" [11] as indicated by our sampling failure rate of 4% which is in the middle of the range from 10% to 0% unsuccessful samplings reported from experienced centers. Our echogenic catheter, which is currently also used in the CVS program at Rotterdam (M. JAHODA, personal communication), could be visualized well in all cases sampled which may explain the low rate of maternal cell contamination in the samples obtained. Only in three cases with male karyotype 1 to 3 cells with 46,XX karyotype were detected in the direct cytogenetic preparation.
No patient in our program was excluded from CVS because of e. g. previous bleeding or discharge during pregnancy or because of uterine or placental position. 7 (= 30%) of the 23 patients with spontaneous abortion had vaginal bleeding before sampling. This difference, however, was not significant. The only selection requirement was intact fetal heart action and a valid indication.
A further analysis of the abortion rates in the group of pregnancies intended to continue in our series shows a clear correlation to the gestational age at the time of sampling. Whereas the spontaneous abortion rates were 7,1% in the cases sampled before 9 and 7,8% after 11 weeks, it was only 3.3% in the group of patients between 9 and 11 weeks. This is in accordance with the findings of HOGGE et al. [4] and JACK-SON [10] . Like others [1, 17] we also found a positive correlation between the risk of CVS and the number of insertions. The abortion rate was 4,1% (13/315) in the group of cases with one insertion, but rose to 6,2% (7/113) after two and 12,7% (9/71) after three or more insertions. Additionally we evaluated the abortion risk in relation to the sample weights. The highest abortion rate (23%) occured in the patients where the sampling failed which might also be influenced by the increased number of insertions in these cases.
It is of interest that the abortion rate in our first 100 consecutive patients who have reached their due date was about 6% which in comparison to the overall results is not suggestive of a pronounced "learning curve" as observed in the beginning of other CVS programs [18, 19] . This may be explained by a proper training period of more than 50 cases in a pre-diagnostic series, careful ultrasound evaluation prior to CVS and the easy handling of our new echogenic catheter.
Summary
Using a newly developed CVS catheter with enhanced echogenicity we performed CVS in 501 consecutive cases. The abortion rate of 4.3% prior to 28 weeks of gestation in this series is within the background rate of controls matched for maternal age. The loss rate was clearly correlated to the number of insertions, time of sampling and sampling success. CVS is safest between 9 and 11 weeks of pregnancy. We recommend to restrict the number of insertions to a maximum of 3. The rate of failed samplings was 4, reflecting a low "aggressiveness in seeking a sample". Complete follow-up of 259 consecutive cases gave no indication of an increased rate of congenital anomalies following CVS in early pregnancy. In our study we also performed cervical swabs, pregnancy hormone testing, maternal serum AFP determination prior to and after CVS as well as maternal AFP screening at 16 weeks of pregnancy together with a detailed sonographic examination. We conclude that CVS can be considered now a safe and reliable diagnostic procedure, but requires further detailed documentation and close follow-up in controlled trials. 
